Cytochrome P450 2D6 Genotyping and Association with Tardive Dyskinesia in Chinese Schizophrenic Patients[*]

Background: The discovery of Cytochrome P450 2D6 (CYP 2D6) polymorphism is implicated in individual differences in drug metabolism rate. Mutation with defective alleles is associated with reduced metabolism of many anti-psychotic drugs metabolized by CYP 2D6. This may contribute to the development of tardive dyskinesia (TD) in patients with prolonged exposure to anti-psychotic drugs. Methods: In this controlled study, the genotype of CYP 2D6*10 alleles, movement disorders and clinical characteristics in 38 Chinese schizophrenic patients with TD were compared with 38 age- and sex-matched schizophrenia patients without TD. Results: There was no significant correlation between CYP 2D6*10 genotypes and TD in men. However, a significant increase in the frequency of CYP 2D6*10 allele was found in female patients with TD. Conclusions: The sex differences in CYP 2D6 genotyping and vulnerability to develop TD suggest that a biological predisposition that affects pharmacokinetics may be more significant in women, whereas other factors may be more important in men.

Schizophrenia - Tardive dyskinesia - CYP 2D6 genotyping

References

• 1 American Psychiatric Association. Diagnostic Criteria for DSM-IV. Washington; 1994
• 2 Andreassen O A, MacEwan T, Gulbrandsen A K, McCreadie R G, Steen V M. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.  Psychopharmacology (Berl). 1997;  131 174-179
• 3 Armstrong M, Daly A K, Blennerhasett R, Ferrier N, Idle J R. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.  Br J Psychiatry. 1997;  170 23-26
• 4 Arthur H, Dahl M L, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.  J Clin Psychopharmacology. 1995;  15 211-216
• 5 Barnes T RE. A rating scale for drug-induced akathisia.  Br J Psychiatry. 1988;  154 672-676
• 6 Bertilsson L, Lou Y Q, Du Y L, Liu Y, Kuang T Y, Liao X M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.  Clin Pharmacol Ther. 1992;  51 388-397
• 7 Bertilsson L. Geographical/Interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.  Clin Pharmacokinet. 1995;  29 192-209
• 8 Chiu H FK, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia and respiratory dyskinesia in Chinese psychiatric patients in Hong Kong.  Am J Psychiatry. 1992;  149 1081-1085
• 9 Garcia-Barcelo M, Chow L Y, Chiu H F, Wing Y K, Lee D TS, Lam K L, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.  Clin Chem. 2000;  46 18-23
• 10 Gough A C, Miles J S, Spurr N K, et al. Identification of the primary gene defect at cytochrome P450 CYP2D locus.  Nature. 1990;  347 773-776
• 11 Guy W. ECDEU Assessment for Psychopharmacology. Washington, DC; HEW Public Health Service 1976: 534-537
• 12 Johansson I, Lundqvist E, Bertilsson L, Dahl M L, Sjoqvist F, Ingelman-Sunderberg M, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.  Proc Natl Acad Sci USA. 1993;  90 11825-11829
• 13 Johansson I, Oscarson M, Yue Q Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.  Mol Pharmacol. 1994;  46 452-259
• 14 Kapitany T, Meszaros K, Lenzinger E, Schindler S D, Barnas C, Fuchs K, et al. Genetic polymorphismus for drug metabolism (CYP 2D6) and tardive dyskinesia in schizophrenia.  Schizophrenia Res. 1998;  32 101-106
• 15 Lin K M, Poland R E, Wan Y J, Smith M W, Lesser I M. The evolving science of pharmacogenetics: clinical and ethnic perspectives.  Psychopharmacol Bull. 1996;  32 205-217
• 16 Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.  Clin Pharmacol Ther. 1999;  65 291-294
• 17 Munitz M-R, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale.  Hosp Com Psychiatry. 1988;  39 1172-1177
• 18 Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.  J Clin Psychopharmacol. 1999;  19 203-208
• 19 Ohmori O, Suzuki T, Kojima H, Shinakai T, Terao T, Mita T, et al. Tardive dyskinesia and debrisoquine-4-hydroxylase (CYP 2D6) genotype in Japanese schizophrenics.  Schizophrenia Res. 1998;  32 107-113
• 20 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psychological Rep. 1962;  10 799-812
• 21 Schooler N R, Kane J M. Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
• 22 Simpson G M, Angus J WS. A rating sclae for extrapyramidal side effects.  Acta Psychiat Scandinavica (Suppl). 1970;  45 11-19
• 23 Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A, et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population.  Psychiatry Clin Neurosc. 1999;  53 593-597
• 24 Statistical Package for Social Sciences SPSS 9.0. Chicago, USA; SPSS Inc. 1999
• 25 Suzuki A, Otani K, Mihara K, Yasui N, Kanebo S, Inoue Y, et al. Effects of the CYP 2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.  Pharmacogenetics. 1997;  7 415-418
• 26 Van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk?.  Acta Psychiatr Scand. 1997;  96 206-216
• 27 Wang S L, Huang J D, Lai M D, Liu B H, Lai M L. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6.  Clin Pharmacol Ther. 1993;  53 410-418
• 28 Wang S L, Lai D M, Lai M L, Huang J D. R296C and other CY2D6 mutations in Chinese.  Pharmacogenetics. 1995;  5 385-388
• 29 Wang S L, Lai M D, Huang J D. G169R mutation diminishes the metabolic activity of Cyp 2D6 in Chinese.  Drug Metab Dispos. 1999;  27 385-388
• 30 Woerner M G, Alvir J M, Saltz B L, Lieberman J A, Kane J M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.  Am J Psychiatry. 1998;  155 1521-1528
• 31 Woerner M G, Mannuzza S, Kane J M. Anchoring the BPRS: an aid to improve reliability.  Psychopharmacol Bulletin. 1998;  24 112-117
• 32 Xie H G, Xu Z H, Luo X, Huang S L, Zeng F D, Zhou H H. Genetic polymorphisms of debrisoquine and S-mephenytoin oxidation metabolism in Chinese populations: a meta-analysis.  Pharmacogenetics. 1996;  6 235-238

1 The work was supported by the Direct Grant for Research of the Chinese University of Hong Kong (Project Code: 2040708).